The purpose of the study was to prospectively evaluate the neuropsychological functioning of children and adolescents receiving a bone marrow transplant (BMT). One hundred and twenty-two children with malignant or nonmalignant disorders and no previous cranial radiation therapy received a pre-BMT neuropsychological evaluation. Surviving children received a 1 year post-BMT neuropsychological evaluation. Patients were placed in a chemotherapy only (chemo) or a chemotherapy and total body irradiation (chemo ؉ TBI) group for statistical analysis. The data were analyzed by t-tests for paired samples. There were no statistically significant differences. Regression analysis failed to identify treatment, age and gender effects. The results suggest that global and specific areas of neuropsychological functioning 1 year post-BMT were not detrimentally affected by chemotherapy or chemotherapy with total body irradiation. Keywords: bone marrow transplantation; neuropsychology; busulfan; total body irradiation; late effects; treatment outcomes
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An expanding donor pool and improvements in supportive care are responsible for improved outcomes although the detrimental impact of treatment-related sequelae remains a significant concern.
1,2 Documented late effects include cardiopulmonary complications, growth hormone deficiency and secondary neoplasms. However, the extent and severity of neuropsychologic late effects have not been empirically established.
that cranial radiation therapy (CRT) detrimentally impacts upon the neuropsychological functioning of some children. 4, 5 The neuropsychological effects of central nervous system prophylactic treatment in childhood leukemia also implicate TBI as a serious risk factor, but because CRT and TBI dosages and fractionation vary substantially, neuropsychological outcomes may also differ.
Studies of neuropsychological functioning of children undergoing BMT report contradictory outcomes. Some studies of chemotherapy plus TBI (chemo ϩ TBI) conditioning protocols report decreases in cognitive and visual-motor functioning test scores 6 and in IQ and adaptive behaviour test scores 1 year post-BMT. 7 Other studies of chemo ϩ TBI conditioning protocols report statistically significant age-related effects including declines in visual-fine motor tests scores among children less than 12 years at 1-6 post-BMT 8 and declines in performance IQ and achievement scores among younger children 1-12 years post-BMT. 9 Finally, other studies of chemo ϩ TBI and chemo conditioning protocols have reported no statistically significant differences in test score differences post-BMT. 3, [10] [11] [12] This study used a prospective design to assess the longitudinal neuropsychological outcome of children undergoing BMT. It was hypothesized that neuropsychological test scores would decrease at 1 year post-BMT in both the chemo and chemo ϩ TBI groups.
Materials and methods

Patients
From 1991 to 1996 all eligible patients (133) undergoing BMT at The Children's Hospital of Philadelphia consented to participate in this prospective study of neuropsychological late effects. No participating patients had received prior CRT. One hundred and twenty-two (122; 92%) patients received a neuropsychological evaluation before BMT conditioning (Time 1). One year post-BMT (Time 2) 50 (41%) patients were deceased. Some deaths in the chemo ϩ TBI group were linked to TBI complications such as pneumonitis. Of the 72 (59%) participating survivors, seven (6%) patients had relapsed and were ineligible for additional study, 11 (9%) patients refused follow-up testing, and three (3%) patients were scheduled, but not tested, prior to the data analysis. Fifty-one (42%) alive and eligible patients were retested. Table 1 provides demographic information and Table 2 summarizes diagnostic data. Seventeen received 1320 cGy, nine received 1200 cGy, and five received 1000 cGy of TBI. In the chemo group, 15 received a busulfan-containing conditioning protocol.
Materials
Based on the child's age, each child was administered a fixed battery of standardized tests.
Bayley Scales of Infant Development (BSID):
Children from 1 month to 2 years, 11 months of age were administered one version of the BSID. [13] [14] [15] During 1993 the BSID-II was published and introduced to the study. Bayley reported moderate correlations between the two versions.
14 Each version yielded a Mental Development Index (MDI; a global indicator of cognitive and language development) and a Psychomotor Development Index (PDI; a global indicator of fine and gross motor development). Scale of Intelligence-Revised (WPPSI-R). 16 Children aged 6-16 years were administered the Wechsler Intelligence Scale for Children-Revised (WISC-R) 17 and then the Wechsler Intelligence Scale for Children-Third Edition (WISC-III). 18 The study shifted to WISC-III soon after publication. Nine children in the chemo ϩ TBI group received the WISC-R at Time 1 and the WISC III at Time 2. Reliability studies show high correlations between the two versions. The psychometric properties of each form are acceptable. 19 
Wechsler Intelligence Scales: Children aged 3-5 years were administered the Wechsler Preschool and Primary
Wide Range Assessment of Memory and Learning-Short Form (WRAML-S):
The WRAML 20 is a standardized test of memory and learning abilities for 5-17 years of age. Four subtests assessing verbal and visual memory and learning yields a total Memory Screening Index (MSI). Reliability and validity data are acceptable.
Developmental Test of Visual-Motor Ingetration (VMI):
The Developmental Test of Visual-Motor Integration 21 was administered to ages 2 years and 9 months, to 17 years and 11 months of age. The VMI requires the child to copy a series of stimulus geometric figures. Psychometric properties are satisfactory.
Procedure
The study was approved by the hospital's Institutional Review Board. Parents signed consent for the study before initiating the conditioning (ie chemo or chemo ϩ TBI) procedure.
Statistical analysis
Test score mean differences pre-and 1 year post-BMT were assessed by t-tests for paired samples. A post hoc analysis using stepwise multiple regressions was conducted to assess the relationship between sex, age, TBI, and chemotherapy (busulfan) and Time 2 test scores.
Results
The analysis of the chemo group and the chemo ϩ TBI group showed no statistically significant differences 1 year post-BMT (Table 3 ). The data did not support the hypothesis that test scores would decrease at the 1 year interval.
The stepwise multiple regression procedure showed Time 1 test scores (FSIQ, MSI, VMI) were the best predictors of Time 2 FSIQ (r ϭ 0.84), MSI (r ϭ 0.89), VMI (r ϭ 0.83) test scores. Other variables (gender, age, chemotherapy) did not account for a significant amount of the variance for Time 2 test scores.
Thirty children who were less than 3 years of age were tested with a version of BSID pre-BMT (BSID ϭ 4; BSID-II ϭ 26). Because the BSID and the Wechsler scales are not theoretically equivalent measures Time 1 BSID and Time 2 Wechsler test scores were not compared. Given the limited data base for children less than 3 years of age, a summary of Time 1 scores are reported. Because most children received the BSID-II and a moderate relationship (MDI ϭ 14 this data offers a useful window from which to understand the cognitive development of very young children prior to BMT. For the chemo group the MDI mean score was 106 (n ϭ 14; s.d. ϭ 22) and the PDI mean score was 90 (n ϭ 7; s.d. ϭ 30). For the chemo ϩ TBI group the MDI mean score was 96 (n ϭ 16; s.d. ϭ 19) and the PDI mean score was 103 (n ϭ 13; s.d. ϭ 48). Four children (13%) survived and were retested Time 2 with BSID II. The sample size was insufficient for statistical analysis. Test scores are reported in Table 4 (BSID II given at Time 1 and Time 2).
Discussion
We found that the neuropsychological outcome of children undergoing BMT remained stable 1 year post-BMT. Tests Table 4 BSID test scores 1 year post-BMT of intelligence, memory and visual-motor functioning failed to identify global or specific decrements in neuropsychological functioning among children receiving chemo and chemo ϩ TBI. The analysis did not reveal a differential effect for treatment (eg busulfan), age, or gender. Most BMT neuropsychological studies assess test score differences among older children. Recent data suggest that children under 6 years of age receiving BMT with or without known neurotoxic conditioning regimens are at risk for decline in cognitive and adaptive behaviour test scores. 7 Our BSID data of this less frequently studied group yield two relevant points. First, pre-BMT scores of mental and motor development for children under 3 years of age were extremely variable. Scores falling within Ϯ1 s.d. spanned a broad range of developmental functioning. Second, BSID-II test scores differences for three of four surviving patients decreased at Time 2. Although not conclusive, these descriptive data are consistent with Kramer et al. 7 Our results are consistent with three other longitudinal studies of neuropsychological outcomes of older children undergoing BMT. 3, 11, 12 Collectively, these prospective studies document that BMT with either chemo or chemo ϩ TBI has no measurably short-term (1 year) neurotoxic effects for children 3 years of age or older. Other longitudinal studies, however, document varying degrees of neurotoxic effects of chemo ϩ TBI at 1 year post-BMT. [6] [7] [8] Our expanding clinical experience with children 1 to 5 years post-BMT also identifies two groups of children. As highlighted by our data analysis, the first group is comprised of the majority of children post-BMT (ie chemo ϩ TBI and chemo) without clinically noteworthy decrements in neuropsychological test scores. The second group is comprised of a small but growing number of children with clinically noteworthy decrements in neuropsychological test scores. This clinical experience fits the pattern of contradictory conclusions across studies.
Research questions intended to provide definitive answers and an area of study plagued by unavoidable small samples may be inadvertently obscuring a more subtle and multifaced pattern of neuropsychological outcome after BMT. The use of chemotherapeutic agents such as busulfan (potentially less neurotoxic) to substitute for TBI (potentially more neurotoxic) emerged from an important effort to alleviate some medical and neuropsychological late effects. The data collectively show that progress has been made in accomplishing this goal. One facet of the emerging pattern suggests that regardless of the conditioning protocol some children do not experience decrements in neuropsychological test scores post-BMT. Moreover, the risk for neuropsychological late effects has been reduced but not eliminated. Some children (more likely those receiving TBI) do experience decrements in neuropsychological functioning but the magnitude is reduced. The San Francisco experience supports this interpretation and may be a harbinger for other prospective studies (including this study because of the small number of surviving younger children). This group reported no test score differences in an earlier analysis 11 and then significant test score differences in a later analysis. 7 With a larger sample size and the corresponding increase in statistical power, and more importantly with longer follow-up, a pattern of mild but significant decrements in neuropsychological test scores became more apparent.
This interpretation has shaped our current 'encouraged but cautious' clinical stance. It is recommended that pediatric BMT protocols include prospective measures of intelligence, memory, and visual-motor development. This proactive and focused psychosocial framework is clinically useful with all children. For some children the assessment helps track and document a return to a 'normal' course of development. For other children the assessment enables clinicians to track the stability and/or changes in cognitive functioning and to collaborate with children, parents and educators in adapting psychoeducational interventions to meet the current and possibly changing needs of the child.
